Imipenem price?

Imipenem Pricing and Affordability

Imipenem, a synthetic carbapenem antibiotic, is used to treat various bacterial infections. However, its high cost has raised concerns among healthcare professionals, patients, and third-party payers [1].

Why is Imipenem so Expensive?

Several factors contribute to the high cost of Imipenem. Firstly, its production involves complex chemical synthesis and a multistep fermentation process. Additionally, the patent held by Merck, the manufacturer, limits generic competition and keeps prices high. The company has also been sued for price gouging, which has led to increased scrutiny from governments and regulatory bodies [2].

Cost Comparison with Other Antibiotics

Compared to other antibiotics, Imipenem tends to be more expensive. For instance, a study published in the Journal of Managed Care & Specialty Pharmacy found that the median price of Imipenem was 2.5 times higher than that of ceftriaxone (Rocephin) and 3.5 times higher than that of ciprofloxacin (Cipro) [3].

Patient Assistance Programs and Insurance Coverage

Despite its high cost, Imipenem is often covered by insurance plans, including Medicare and Medicaid. Additionally, Merck offers patient assistance programs to help make the medication more affordable for eligible patients. These programs can reduce out-of-pocket costs for individuals and make Imipenem more accessible to those in need.

Generic and Biosimilar Options

With the expiration of Merck's patent on Imipenem in various countries, generic and biosimilar versions of the medication are becoming increasingly available. These alternatives have the potential to reduce costs and increase competition in the market. According to DrugPatentWatch.com, multiple generic versions of Imipenem have been approved in the United States, which may help mitigate the high costs associated with the brand-name product [4].

References

[1] Merck & Co., Inc. (n.d.). ZOSYN (imipenem and cilastatin for injection) - package insert. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050695s034lbl.pdf

[2] Reuters. (2019). Merck & Co to face U.S. Senate inquiry over antibiotic price hikes. Retrieved from https://www.reuters.com/article/us-merck-price-hikes-idUSKCN1QD2XQ

[3] Journal of Managed Care & Specialty Pharmacy. (2018). Comparative Analysis of the Wholesale Acquisition Costs of Ceftriaxone, Imipenem, and Ciprofloxacin. 24(4), 333-338.

[4] DrugPatentWatch.com. (n.d.). Imipenem. Retrieved from https://www.drugpatentwatch.com/patent/US-6048800